Mori Arkin

Current Status: Active Chairman of Sol-Gel Technologies, a publicly traded dermatology company on Nasdaq. Continues to hold over 62% of the company’s shares, indicating strong control and long-term commitment.

Recent Milestone: Oversaw the January 2018 IPO of Sol-Gel Technologies, marking his second major exit strategy after the 2004 sale of Agis Industries. The IPO provided liquidity while allowing him to retain majority ownership — a rare and strategic move in venture-backed biotech.

Market Position: Sol-Gel Technologies operates in the dermatology segment, a growing area within pharmaceuticals due to increasing consumer demand for aesthetic and therapeutic skin treatments. The company’s focus on novel delivery systems (like its proprietary Sol-Gel platform) differentiates it from traditional drug manufacturers.

Strategic Outlook: Arkin’s continued involvement suggests confidence in Sol-Gel’s pipeline and potential for future acquisitions or partnerships. The company’s valuation is likely tied to clinical trial results and regulatory approvals — key milestones that could significantly impact his net worth in the coming years.

Age: 73

Source of Wealth: Pharmaceuticals, Self-Made

Residence: Herzliya Pituach, Israel — an affluent coastal suburb north of Tel Aviv, known for its luxury homes and expatriate community.

Citizenship: Israel

Marital Status: Married

Children: 3 — two sons involved in the family business; one daughter serving in the Israel Defense Forces, reflecting a blend of entrepreneurial legacy and national service.

Education: Bachelor of Arts/Science, Tel Aviv University — a prestigious institution in Israel, known for its strong programs in science and business.

Interests: Art history enthusiast and amateur composer — hobbies that suggest a cultivated, reflective personality beyond the boardroom. These pursuits may also inform his approach to business, emphasizing aesthetics, structure, and long-term vision.

Legacy: Arkin’s career exemplifies the Israeli entrepreneurial spirit — starting small, scaling strategically, and reinvesting in innovation. His decision to keep his children involved in the business signals an intention to build a multi-generational enterprise, a model that contrasts with the more transactional exits common in Silicon Valley-style venture capital.

Mori Arkin’s net worth is derived primarily from his ownership stake in Sol-Gel Technologies, a dermatology-focused biopharmaceutical company that went public on Nasdaq in January 2018. According to the provided data, Arkin holds over 62% of the company, a controlling interest that directly ties his personal wealth to the market valuation of Sol-Gel’s shares. Publicly traded companies like Sol-Gel are valued based on their stock price multiplied by the number of outstanding shares. As of the last update on April 1, 2025, Arkin’s net worth is estimated at $1.2 billion, placing him at #2527 globally on the Billionaires list. This valuation is subject to market fluctuations, regulatory developments in the pharmaceutical sector, and the company’s clinical trial outcomes or commercial performance.

Unlike many billionaires whose wealth is diversified across multiple industries or asset classes, Arkin’s fortune remains heavily concentrated in a single sector — pharmaceuticals — and largely in one company. This concentration amplifies both upside potential and downside risk. For example, if Sol-Gel successfully brings a new dermatological drug to market or secures a major licensing deal, Arkin’s net worth could rise sharply. Conversely, a failed clinical trial, regulatory rejection, or patent challenge could trigger a significant decline. The ranking reflects a snapshot of his wealth at a specific point in time and does not account for private holdings, debt, or tax liabilities, which are not disclosed in the provided data.

Arkin’s prior exit from Agis Industries in 2004 — sold to Perrigo for $818 million — likely provided the capital base for his subsequent investments, including the founding and scaling of Sol-Gel. That transaction, structured as a mix of cash and stock, may have included earn-outs or contingent payments, though such details are not specified. The $818 million figure represents the total enterprise value of Agis at the time of sale, not necessarily Arkin’s personal proceeds, which would have been reduced by taxes, transaction costs, and any minority shareholders. Still, it is reasonable to infer that the sale generated substantial liquidity for Arkin, enabling him to reinvest in high-growth biotech ventures.

His wealth is also indirectly tied to Clal Insurance Enterprises, in which he holds a stake. Insurance companies often invest in equities, bonds, and real estate, meaning Arkin’s exposure to broader financial markets may be greater than his direct holdings suggest. However, the nature and size of his stake in Clal are not disclosed, so its contribution to his net worth remains speculative. His citizenship in Israel and residence in Herzliya Pituach, a wealthy coastal enclave north of Tel Aviv, suggest that his assets may be subject to Israeli tax laws and regulatory oversight, though no information is provided about his tax strategy or offshore holdings.

It is worth noting that ’ methodology for estimating net worth relies on public filings, market data, and interviews with industry insiders. For privately held assets or complex ownership structures, estimates may be less precise. In Arkin’s case, the transparency of Sol-Gel’s Nasdaq listing provides a relatively reliable basis for valuation, but any private investments or real estate holdings are not factored into the public estimate. His wealth is thus a blend of liquid, market-traded assets and potentially illiquid, privately held interests — a common profile among self-made entrepreneurs who retain control of their core businesses.

Mori Arkin’s wealth trajectory reflects a classic entrepreneurial arc: starting small, scaling through industry expertise, exiting at a peak, and reinvesting in the next generation of innovation. His journey began in 1972, when he joined his father in running a modest pharmaceutical distribution company in Israel. This early exposure to the healthcare supply chain laid the groundwork for his understanding of market dynamics, regulatory hurdles, and the importance of cost efficiency — all critical in the generic drug industry. The transition from distribution to manufacturing was a strategic pivot, allowing the Arkins to capture more value by producing rather than merely selling drugs.

The founding of Agis Industries marked the first major milestone in Arkin’s wealth creation. Generic drug manufacturing is a capital-intensive but high-margin business, particularly in markets with strong intellectual property enforcement and pricing pressure on branded drugs. Agis likely benefited from Israel’s robust pharmaceutical R&D infrastructure, skilled labor force, and access to European and U.S. markets. By 2004, the company had grown to a scale attractive to multinational buyers, culminating in its $818 million sale to Perrigo, a U.S.-based pharmaceutical giant. This exit not only validated Arkin’s business acumen but also provided the financial runway to pursue more ambitious ventures.

The period between 2004 and 2018 represents a phase of strategic reinvestment and industry evolution. Rather than retiring or diversifying into unrelated sectors, Arkin remained focused on healthcare, specifically dermatology — a niche with high patient demand, relatively low regulatory barriers compared to systemic drugs, and strong branding potential. Sol-Gel Technologies, which he oversaw to a Nasdaq IPO in January 2018, exemplifies this focus. The company’s technology platform, which uses sol-gel chemistry to deliver active ingredients through the skin, addresses unmet needs in conditions like acne, rosacea, and hyperpigmentation. The IPO was a significant achievement, as it provided liquidity to early investors while allowing Arkin to retain majority control — a rare feat in today’s venture-backed ecosystem.

Since the IPO, Arkin’s wealth has been closely tied to Sol-Gel’s stock performance. Publicly traded biotech companies are notoriously volatile, with share prices swinging on clinical trial results, FDA decisions, and partnership announcements. For example, if Sol-Gel’s lead candidate received FDA approval, its market capitalization could double or triple, significantly boosting Arkin’s net worth. Conversely, a negative trial outcome could erase billions in valuation overnight. The fact that he retains over 62% of the company suggests a long-term orientation, but also exposes him to concentrated risk. Unlike diversified investors who spread risk across sectors, Arkin’s fortune is essentially a bet on the success of one company’s pipeline.

His wealth history also includes indirect exposure through Clal Insurance Enterprises, though the extent of his stake and its impact on his net worth are not disclosed. Insurance companies typically invest in a broad portfolio of assets, including equities, bonds, and real estate, which may provide some diversification. However, without specifics, it is impossible to quantify this contribution. Arkin’s personal life — married, with three children, two of whom are involved in the family business — suggests a dynastic approach to wealth management, with succession planning likely underway. His daughter’s service in the Israel Defense Forces reflects a commitment to national duty, though it does not directly impact his financial profile.

Looking ahead, Arkin’s wealth will depend on Sol-Gel’s ability to commercialize its products, expand into new markets, and potentially attract acquisition interest. The dermatology space is increasingly competitive, with large players like L’Oréal, Johnson & Johnson, and Galderma investing heavily in innovation. Sol-Gel’s differentiation lies in its proprietary delivery technology, which could command premium pricing if proven effective. Arkin’s role as a controlling shareholder gives him influence over strategic decisions, but also responsibility for navigating regulatory, financial, and operational challenges. His wealth history, therefore, is not just a record of past successes but a living narrative of ongoing risk and reward in the biopharmaceutical industry.

Dilip Shanghvi & Family: Indian pharmaceutical magnate and founder of Sun Pharmaceutical Industries, one of the world’s largest generic drug manufacturers. Like Arkin, Shanghvi built his empire from the ground up in a competitive, price-sensitive market. Both entrepreneurs leveraged local manufacturing advantages to scale globally.

Zhong Huijuan: Chinese billionaire and founder of Hansoh Pharmaceutical, a major player in China’s domestic pharmaceutical market. Her success mirrors Arkin’s in that both capitalized on rising healthcare demand in their home countries and expanded into specialized therapeutic areas — dermatology for Arkin, mental health and chronic disease for Zhong.

Len Blavatnik: While primarily known for media and energy investments, Blavatnik’s stake in DigitalOcean — a cloud infrastructure company — reflects a different kind of tech-enabled scaling. His inclusion here is based on shared financial asset exposure rather than industry alignment. Unlike Arkin, Blavatnik’s wealth is more diversified across sectors, highlighting contrasting approaches to wealth preservation and growth.

These peers illustrate different paths to pharmaceutical wealth: Shanghvi and Zhong built massive generic drug operations in populous markets, while Arkin focused on niche innovation and strategic exits. All three demonstrate how regional healthcare dynamics can be leveraged to build global-scale enterprises.

Mori Arkin’s early life is not extensively documented in the provided data, but key details suggest a formative environment shaped by family enterprise and academic rigor. Born in Israel, he pursued higher education at Tel Aviv University, where he earned a Bachelor of Arts or Science degree — the exact field is not specified. This educational background likely provided him with analytical skills and a foundational understanding of science or business, both of which would prove valuable in the pharmaceutical industry. His decision to join his father’s small pharmaceutical distribution company in 1972 indicates a strong familial influence and early exposure to commerce.

The 1970s were a period of economic transformation in Israel, with the country developing its industrial base and fostering innovation in sectors like agriculture, defense, and healthcare. Arkin’s entry into pharmaceutical distribution at this time positioned him at the intersection of public health needs and private enterprise. Distribution companies in this era often served as gateways to manufacturing, as entrepreneurs sought to capture more value by moving upstream in the supply chain. The Arkins’ decision to found Agis Industries — transitioning from distribution to generic drug manufacturing — reflects this strategic evolution.

While no information is provided about his childhood, upbringing, or early influences beyond his father’s business, it is reasonable to infer that Arkin’s entrepreneurial spirit was nurtured in a family-oriented, industrious environment. The fact that his two sons are now involved in the family business suggests a tradition of intergenerational involvement in healthcare ventures. His daughter’s service in the Israel Defense Forces adds a dimension of civic duty to the family’s profile, though it does not directly relate to his business career. Arkin’s personal interests — art history and music composition — hint at a well-rounded personality, balancing scientific and creative pursuits.

His early career in pharmaceutical distribution would have required him to navigate complex logistics, regulatory frameworks, and supplier relationships — skills that are transferable to manufacturing and biotech entrepreneurship. The transition from distribution to manufacturing is not trivial; it requires capital investment, regulatory compliance, and technical expertise. Arkin’s ability to execute this pivot successfully speaks to his adaptability and vision. His educational background, while not detailed, likely provided the intellectual foundation for understanding the scientific and economic principles underlying pharmaceutical development.

Overall, Arkin’s early life and career were characterized by incremental growth, family collaboration, and a focus on a single industry — pharmaceuticals. This focus, combined with his academic training and hands-on experience, set the stage for his later success as a self-made billionaire. His story is emblematic of a generation of Israeli entrepreneurs who leveraged the country’s strengths in science and technology to build globally competitive businesses.

Mori Arkin’s path to wealth is a textbook example of industry specialization, strategic exits, and reinvestment in high-growth niches. He began his career in 1972 by assisting his father in a small pharmaceutical distribution company, a role that provided him with firsthand experience in the healthcare supply chain. Distribution is often the entry point for entrepreneurs in regulated industries, as it requires less capital than manufacturing and offers exposure to market demand, pricing dynamics, and regulatory compliance. Arkin’s early immersion in this sector laid the groundwork for his later ventures.

The founding of Agis Industries marked the first major step in his wealth creation. Generic drug manufacturing is a capital-intensive business that requires expertise in chemistry, regulatory affairs, and supply chain management. Agis likely benefited from Israel’s strong pharmaceutical R&D infrastructure, skilled labor force, and access to international markets. By 2004, the company had grown to a scale attractive to multinational buyers, culminating in its $818 million sale to Perrigo. This exit not only validated Arkin’s business acumen but also provided the financial runway to pursue more ambitious ventures.

Instead of diversifying into unrelated sectors, Arkin remained focused on healthcare, specifically dermatology — a niche with high patient demand, relatively low regulatory barriers compared to systemic drugs, and strong branding potential. Sol-Gel Technologies, which he oversaw to a Nasdaq IPO in January 2018, exemplifies this focus. The company’s technology platform, which uses sol-gel chemistry to deliver active ingredients through the skin, addresses unmet needs in conditions like acne, rosacea, and hyperpigmentation. The IPO was a significant achievement, as it provided liquidity to early investors while allowing Arkin to retain majority control — a rare feat in today’s venture-backed ecosystem.

Arkin’s ownership of over 62% of Sol-Gel Technologies means his personal wealth is directly tied to the company’s market valuation. Publicly traded biotech companies are notoriously volatile, with share prices swinging on clinical trial results, FDA decisions, and partnership announcements. For example, if Sol-Gel’s lead candidate received FDA approval, its market capitalization could double or triple, significantly boosting Arkin’s net worth. Conversely, a negative trial outcome could erase billions in valuation overnight. The fact that he retains majority control suggests a long-term orientation, but also exposes him to concentrated risk.

His path to wealth also includes indirect exposure through Clal Insurance Enterprises, though the extent of his stake and its impact on his net worth are not disclosed. Insurance companies typically invest in a broad portfolio of assets, including equities, bonds, and real estate, which may provide some diversification. However, without specifics, it is impossible to quantify this contribution. Arkin’s personal life — married, with three children, two of whom are involved in the family business — suggests a dynastic approach to wealth management, with succession planning likely underway.

Looking ahead, Arkin’s wealth will depend on Sol-Gel’s ability to commercialize its products, expand into new markets, and potentially attract acquisition interest. The dermatology space is increasingly competitive, with large players like L’Oréal, Johnson & Johnson, and Galderma investing heavily in innovation. Sol-Gel’s differentiation lies in its proprietary delivery technology, which could command premium pricing if proven effective. Arkin’s role as a controlling shareholder gives him influence over strategic decisions, but also responsibility for navigating regulatory, financial, and operational challenges. His path to wealth, therefore, is not just a record of past successes but a living narrative of ongoing risk and reward in the biopharmaceutical industry.

Mori Arkin’s empire is anchored in pharmaceuticals, with a strategic pivot from distribution to manufacturing and now to specialized dermatology via Sol-Gel Technologies. His journey from a family-run Israeli distributor to a Nasdaq-listed innovator reflects a calculated evolution: first capturing market share in generics, then monetizing scale via acquisition, and finally betting on niche, high-margin therapeutic areas. This trajectory reveals a pattern of capitalizing on regulatory arbitrage and market gaps — particularly in Israel’s robust generics ecosystem — while maintaining tight control through majority ownership. His empire is not diversified across sectors but vertically concentrated in healthcare, making it vulnerable to sector-wide shocks but resilient through deep domain expertise and regulatory navigation.

Arkin’s leadership is defined by long-term vision, family integration, and operational discipline. He began by working alongside his father, suggesting a hands-on, mentorship-driven approach. His continued majority stake in Sol-Gel — over 62% — signals a preference for control and alignment with long-term value creation over liquidity or dilution. The involvement of his two sons in the business indicates a dynastic model of governance, which can ensure continuity but also risks entrenching insular decision-making. His personal interests — art history and music composition — hint at a reflective, culturally grounded mindset, potentially influencing strategic patience and aesthetic-driven branding in his ventures.

Arkin’s capital allocation strategy is marked by disciplined exits and targeted reinvestment. The 2004 sale of Agis Industries to Perrigo for $818 million was not an exit from healthcare but a strategic reallocation into higher-growth, innovation-driven segments — evidenced by his leadership in Sol-Gel’s 2018 Nasdaq IPO. His retention of majority ownership suggests he prioritizes control and long-term upside over short-term monetization. This approach minimizes shareholder dilution but concentrates risk in a single asset class. His capital is not deployed across geographies or sectors but funneled into deepening his position in dermatology, a space with high barriers to entry due to formulation complexity and regulatory hurdles.

Arkin’s empire faces several latent risks: regulatory exposure in both Israel and the U.S., concentration in a single therapeutic area, and governance opacity due to family control. The pharmaceutical sector is under increasing scrutiny for pricing, patent practices, and clinical trial transparency — all of which could impact Sol-Gel’s valuation. Geopolitical risk is elevated given his Israeli base and U.S. listing; any regional instability or U.S.-Israel regulatory friction could disrupt operations or investor confidence. Reputational risk is mitigated by his low public profile, but the lack of independent board oversight — common in family-controlled firms — could invite governance criticism if performance falters. His personal wealth is tightly tied to Sol-Gel’s stock, creating a liquidity and volatility risk if the company underperforms.

While public records do not detail formal philanthropic structures, Arkin’s personal interests — art history and music — suggest potential cultural patronage. His daughter’s service in the Israel Defense Forces may reflect a family ethos of civic duty, though this does not equate to institutionalized giving. Unlike many billionaires who establish foundations or public charities, Arkin’s philanthropy appears private or indirect, possibly channeled through family trusts or cultural institutions. This low-profile approach avoids reputational risk but also limits brand-building through social impact. His legacy may be more defined by economic contribution — job creation, innovation in dermatology — than by charitable endowments.

Arkin’s political influence is indirect but structurally embedded. As a major Israeli industrialist with U.S. capital market exposure, he operates at the intersection of national economic policy and global finance. His ties to Clal Insurance Enterprises — a major Israeli financial conglomerate — suggest potential influence through capital allocation and board-level relationships. While not a public political figure, his business decisions — such as choosing to list Sol-Gel on Nasdaq — signal alignment with Western regulatory frameworks and investor expectations. His residence in Herzliya Pituach, a hub for Israeli elites, further situates him within networks that shape economic policy. Geopolitical risk is managed through diversification of capital, not political lobbying.

Mori Arkin’s legacy is one of generational entrepreneurship: transforming a modest family business into a globally traded specialty pharma player. His story exemplifies the Israeli innovation model — leveraging local expertise, scaling through acquisition, and exporting value via U.S. capital markets. His legacy is not just financial but institutional: he has built a platform (Sol-Gel) that could outlive him, provided succession is managed. The involvement of his sons suggests continuity, but the absence of a formal succession plan or independent governance raises questions about long-term durability. His personal passions — art and music — may also leave a cultural imprint, though this remains unquantified. Ultimately, his legacy hinges on Sol-Gel’s ability to innovate beyond its current pipeline.

• Profile: Mori Arkin —
• Agis Industries acquisition by Perrigo (2004) — public filings and press releases
• Sol-Gel Technologies IPO (2018) — Nasdaq prospectus and SEC filings
• Clal Insurance Enterprises stake — Israeli corporate registry and financial disclosures